Study may explain why once-promising cancer drugs failed

Nearly two decades after a class of once-promising cancer drugs called MMP inhibitors mysteriously failed in clinical trials, scientists think they may have an explanation for what went wrong. The findings in C. elegans worms could lead to better ways to prevent the first steps of metastasis, the spread of the disease responsible for 90 percent of cancer deaths.

MMP inhibitors were aimed at blocking a group of enzymes long thought key to cancer's spread. Called matrix metalloproteinases, the enzymes help dissolve the tough outer membrane that surrounds both tumors and healthy tissues, allowing cancer cells to escape from their original locations and set up shop in other organs.

Yet despite promising results in mice, MMP inhibitors didn't help people with cancer live longer and some patients developed serious side effects.

The new findings, from a team led by biology professor David Sherwood at Duke University, suggest that invasive cells switch to brute force and build a battering ram when their dissolving enzymes aren't available.

The study appears online January 24 in the journal Developmental Cell.

To metastasize, a tumor cell must first penetrate a dense sheet-like mesh of proteins and other molecules called the basement membrane, which surrounds tissues like a Kevlar wrapper.

Sherwood and his team study a similar process in transparent 1-millimeter worms, which - unlike human tumors - allow researchers to watch invading cells in action.

Normal worm cells use their MMP enzymes to help cut through the matrix of proteins in the basement membrane like molecular scissors, the researchers say. But cells in "knockout" worms lacking the MMP enzymes instead build a large protrusion that pummels and smashes its way through with brute force, said research scientist Laura Kelley, who led the experiments.

Normally the invading cell pushes through a narrow hole, "kind of like the escape tunnel in 'The Shawshank Redemption,'" Sherwood said. "But in knockout worms it's more like the Kool-Aid Man when he busts through walls."

The researchers also found that the protrusion is filled with stiff networks of actin filaments for a harder-hitting punch. To fuel the blows, the cell also moves mitochondria - the power plants of the cell - to the site of the ram.

The team also developed a screening technique that enabled them to identify and target a mitochondrial gene that invasive cells rely on in the absence of MMPs, and were able to prevent the cells from breaking through.

The researchers hope their work in worms will identify drug targets that could one day be tested in combination with MMP inhibitors to better treat metastasis in humans.

If researchers can develop drugs that inhibit both MMP enzymes and the battering rams, they may be able to more effectively block cell invasion and keep cancer from spreading.

Laura Kelley, Qiuyi Chi, Rodrigo Cáceres, Eric Hastie, Adam Schindler, Yue Jiang, David Matus, Julie Plastino and David Sherwood.
Adaptive F-actin Polymerization and Localized ATP Production Drive Basement Membrane Invasion in the Absence of MMPs.
Developmental Cell, January 24, 2019. DOI: 10.1016/j.devcel.2018.12.018.

Most Popular Now

Novartis receives FDA approval for Mayzent® (sipon…

Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple scl...

Compound that kills drug-resistant fungi is isolat…

Antimicrobial and antifungal resistance, which describe the ability of bacteria and other pathogens to resist the effects of drugs to which they were once sensitive, is a...

First bacterial genome created entirely with a com…

All the genome sequences of organisms known throughout the world are stored in a database belonging to the National Center for Biotechnology Information in the United Sta...

Liver, colon cancer cells thwarted by compounds de…

The plant that adds flavor, color and bitterness to beer also produces a primary compound that thwarts cancer cells, and two important derivatives of the compound do as w...

Clinical trial finds therapy to be well-tolerated …

A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated...

Immune cells fighting blood cancer visualized for …

When cancer escapes the immune system, our defenses are rendered powerless and are unable to fight against the disease. Chimeric antigen receptor T cells (CAR T cells) re...

FDA approves treatment for patients with a type of…

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called no...

Boehringer Ingelheim announces FDA and EMA regulat…

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and E...

Selumetinib granted US Breakthrough Therapy Design…

AstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration (FDA) ha...

Novartis adds clinical and preclinical anti-inflam…

Novartis announced that it is adding to its broad portfolio of immunomodulatory medicines with the planned acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC fo...

Forxiga approved in Japan for type-1 diabetes

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T...

Novartis continues transformation into a leading m…

Novartis today completed the spin-off of the Alcon eye care devices business through a dividend-in-kind distribution to holders of Novartis shares and ADRs (American Depo...